MARLBOROUGH, Mass.--(BUSINESS WIRE)--Jan. 31, 2006--Sepracor Inc. (Nasdaq: SEPR) today announced its consolidated financial results for the fourth quarter and full year 2005. For the three months ended December 31, 2005, Sepracor’s consolidated revenues were approximately $311.1 million, of which revenues from Sepracor’s pharmaceutical product sales were approximately $302.9 million (XOPENEX(R) brand levalbuterol HCl Inhalation Solution revenues were $146.0 million, XOPENEX HFA(TM) brand levalbuterol tartrate Inhalation Aerosol revenues were $12.0 million and LUNESTA(TM) brand eszopiclone revenues were $144.9 million). Net income for the fourth quarter of 2005 was approximately $37.2 million, or $0.32 per diluted share. These consolidated results compare with consolidated revenues of $131.4 million, of which revenues from Sepracor’s pharmaceutical product sales (XOPENEX Inhalation Solution) were approximately $117.2 million, and a net loss of $33.7 million, or $0.33 per diluted share, for the three months ended December 31, 2004.
